Keeping it in the family: Rentschler to offer fill and finish services

By Flora Southey contact

- Last updated on GMT

iStock/pkujiahe
iStock/pkujiahe

Related tags: Contract, Future

Rentschler Biotechnologie has entered into a strategic partnership with Rentschler Fill Solutions to offer its clients aseptic fill and finish services.

The companies, while both owned by the Rentschler families, are unique entities.

According to the Germany-based contract development and manufacturing organisation (CDMO), the agreement, which makes Rentschler Fill Solutions its exclusive partner for fill and finish requirements, offers clients a simpler solution.

“The main advantage of this partnership is that the client won’t need to change providers. The client will have one contact person, the strategic agreement offers a one-stop solution,” ​said Rentschler Biotechnologie spokesperson Marion Schrader.

Rentschler Biotechnologie CEO said the partnership responds to a predicted market need.

“In order to manage the expected growth and provide clients with new, scalable, state-of-the-art technologies and facilities, this new partnership with Rentschler Fill Solutions will allow us to meet today’s and the future needs of our clients,” ​said CEO Frank Mathias.

Liquid and lyophilized biopharmaceuticals

Austria-based Rentschler Fill Solutions will employ vials from DIN2R up to 50ml for aseptic filling of liquid or lyophilized biopharmaceuticals in small to medium-sized batches.

According to the company, up to 60,000 vials per batch can be filled, and timelines and batch sizes tailored and flexibly scaled.

Rentschler Fill Solutions general manager Reinhold Elsaesser said the firm will address clinical and market needs with regards to capacity, scalability, safety and purity.

Rentschler Fill Solutions will begin operations mid-2018.

Related news

Show more

Related products

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Follow us

Products

View more

Webinars